Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2023-507901-32-00 | Other Identifier | EU CT |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine the safety and pharmacokinetics of Etentamig (ABBV-383) in adult participants with relapsed/refractory (R/R) MM.
Etentamig (ABBV-383) is an investigational drug being developed for the treatment of R/R MM. This study is broken into 3 Arms: Arm A with 2 parts and Arm B as an expansion. Participants will receive ABBV-383 as a subcutaneous (SC) injection and intravenous (IV) infusion in Arm A and SC injections of ABBV-383 in Arm B. Around 55 adult participants with relapsed/refractory multiple myeloma will be enrolled at approximately 15 sites across the world
In Arm A participants will receive one of two doses of Etentamig (ABBV-383) as an SC injection and (IV) infusions, during the 151 week study duration. In Arm B, participants will receive the selected dose from Arm A as SC injections, during the 151 week study duration.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and questionnaires.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Etentamig Dose A | Experimental | Participants will receive Dose A of Etentamig as a subcutaneous (SC) injection and intravenous (IV) infusions, during the 151 week study duration. |
|
| Etentamig Dose B | Experimental | Participants will receive Dose B of Etentamig as an SC injection and IV infusions, during the 151 week study duration. |
|
| Etentamig Expansion | Experimental | Participants will receive the selected dose from Arm A of Etentamig as SC injections, during the 151 week study duration. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Subcutaneous (SC) Etentamig | Drug | SC Injection |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants Experiencing Cytokine Release Syndrome (CRS) Events | Cytokine Release Syndrome events will be graded using American Society for Transplantation and Cellular Therapy (ASTCT), with a higher grade indicating higher severity. | Up to 2 cycles (56 days) |
| Percentage of Participants Experiencing Immune Cell-Associated Neurotoxicity Syndrome (ICANS) Events | ICANS events will be graded using ASTCT, with a higher grade indicating higher severity. | Up to 2 cycles (56 days) |
| Maximum Observed Concentration (Cmax) of ABBV-383 | Cmax of ABBV-383. | Up to 32 weeks |
| Time to Cmax (Tmax) of ABBV-383 | Tmax of ABBV-383. | Up to 32 weeks |
| Trough Concentration (Ctrough) of ABBV-383 | Ctrough of ABBV-383. | Up to 32 weeks |
| Area Under the Plasma Concentration-time Curve (AUC) of ABBV-383 | AUC of ABBV-383. | Up to 24 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Overall Response Rate (ORR) | The ORR is defined as the percentage of participants who achieve a best overall response of confirmed PR or better determined by international myeloma working group (IMWG) criteria, prior to the initiation of subsequent myeloma therapy. | Up to 24 months |
| Percentage of Participants Achieving Stringent Complete Response (sCR), |
Not provided
Inclusion Criteria:
Exclusion Criteria:
- Received B-cell maturation antigen (BCMA)xCD3 bispecific antibody.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| ABBVIE INC. | AbbVie | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mayo Clinic Arizona /ID# 260799 | Phoenix | Arizona | 85054 | United States | ||
| Mayo Clinic Hospital Jacksonville /ID# 262808 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Intravenous (IV) Etentamig | Drug | IV Infusion |
|
sCR is defined as participants achieving negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, < 5% plasma cells in bone marrow, normal free light chain (FLC) ratio, and Absence of clonal cells in bone marrow by immunohistochemistry. |
| Up to 24 months |
| Percentage of Participants Achieving Complete Response (CR) | CR is defined as participants achieving negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, < 5% plasma cells in bone marrow, and for participants in whom the only measurable disease is by serum FLC levels, a normal FLC ratio. | Up to 24 months |
| Percentage of Participants Achieving Very Good Partial Response (VGPR) | VGPR is defined as participants achieving serum and urine M-protein detectable by immunofixation but not on electrophoresis, >= 90% reduction in serum M-protein plus urine, and for participants in whom the only measurable disease is by serum FLC levels, >= 90% decrease in the difference between involved and uninvolved FLC levels. | Up to 24 months |
| Percentage of Participants Achieving Partial Response (PR) | PR is defined as participants achieving >= 50% reduction of serum M-protein, reduction in 24-hour urinary M-protein by >= 90% as noted in the protocol, >= 50% reduction in the size of soft tissue plasmacytomas is also required, if present at baseline. | Up to 24 months |
| Duration of Response (DoR) | DoR will be defined as the time from the date of first response [partial response (PR) + VGPR + complete response (CR) + stringent complete response (sCR)] to the earliest occurrence of progressive disease, or death, whatever occurs first. | Up to 24 months |
| Progression Free Survival (PFS) | PFS is defined as the duration from the date of randomization to the date of confirmed disease progression (PD) per international myeloma working group (IMWG) criteria, or death, whichever occurs first. | Up to 24 months |
| Time to Response (TTR) | TTR is defined as the number of months from the date of first dose to the date of best overall response of CR or PR ('responders') determined by IMWG criteria. | Up to 24 months |
| Immunogenicity of ABBV-383 as Determined by Anti-Drug Antibodies (ADAs) | Incidence and concentration of ADAs. | Up to 27 months |
| Immunogenicity of ABBV-383 as Determined by Neutralizing Anti-Drug Antibodies (NAbs) | Incidence and concentration of NAbs. | Up to 27 months |
| Jacksonville |
| Florida |
| 32224 |
| United States |
| Sylvester Comprehensive Cancer Center /ID# 260798 | Miami | Florida | 33136-1002 | United States |
| University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 261050 | Ann Arbor | Michigan | 48109 | United States |
| Mayo Clinic - Rochester /ID# 262807 | Rochester | Minnesota | 55905-0001 | United States |
| Atrium Health Wake Forest Baptist Medical Center /ID# 260807 | Winston-Salem | North Carolina | 27157 | United States |
| Wisconsin Medical Center /ID# 261085 | Milwaukee | Wisconsin | 53226 | United States |
| Universitaetsklinikum Frankfurt /ID# 260442 | Frankfurt am Main | Hesse | 60590 | Germany |
| Universitaetsklinikum Koeln /ID# 260445 | Cologne | North Rhine-Westphalia | 50937 | Germany |
| Universitaetsklinikum Hamburg-Eppendorf /ID# 260444 | Hamburg | 20246 | Germany |
| Hadassah Medical Center-Hebrew University /ID# 261446 | Jerusalem | Jerusalem | 91120 | Israel |
| The Chaim Sheba Medical Center /ID# 261699 | Ramat Gan | Tel Aviv | 5265601 | Israel |
| Tel Aviv Sourasky Medical Center /ID# 261525 | Tel Aviv | Tel Aviv | 6423906 | Israel |
| Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital /ID# 265286 | Nagoya | Aichi-ken | 466-8650 | Japan |
| Kindai University Hospital /ID# 266016 | Sakai-shi | Osaka | 590-0197 | Japan |
| ID | Term |
|---|---|
| D009101 | Multiple Myeloma |
| ID | Term |
|---|---|
| D054219 | Neoplasms, Plasma Cell |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D020141 | Hemostatic Disorders |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D010265 | Paraproteinemias |
| D001796 | Blood Protein Disorders |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D006474 | Hemorrhagic Disorders |
| D008232 | Lymphoproliferative Disorders |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D007279 | Injections, Subcutaneous |
| ID | Term |
|---|---|
| D007267 | Injections |
| D004333 | Drug Administration Routes |
| D004358 | Drug Therapy |
| D013812 | Therapeutics |
Not provided
Not provided